|
Jul 17
|
Top Midday Decliners
|
|
Jul 17
|
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
|
|
Jul 15
|
Sector Update: Health Care Stocks Edge Lower Late Afternoon
|
|
Jul 15
|
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
|
|
Jun 14
|
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
|
|
May 21
|
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
|
|
May 9
|
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
|
|
May 2
|
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
|
|
Apr 30
|
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
|
|
Apr 24
|
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
|
|
Apr 22
|
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
|
|
Apr 19
|
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
|
|
Apr 12
|
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Apr 9
|
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
|
|
Mar 27
|
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
|
|
Mar 20
|
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 12
|
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
|
|
Mar 12
|
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
|
|
Mar 11
|
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
|